Allergy Immunotherapy for the Reduction of Asthma (AIR)
Efficacy of Allergy Immunotherapy in Preventing Asthma Morbidity in Atopic, Wheezing Children (Age 18 Months - 3 Years)
Sponsor: Albert Einstein College of Medicine
A PHASE1/PHASE2 clinical study on Allergy and Asthma, this trial is completed. The trial is conducted by Albert Einstein College of Medicine and has accumulated 12 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Suspended → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Suspended PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Suspended PHASE1_PHASE2
-
Aug 2017 — May 2018 [monthly]
Suspended PHASE1_PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Suspended PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1_PHASE2
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Einstein College of Medicine
- Jacobi Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .